Brief: Bioxyne Says FY25 Unaudited Revenue Of A$29.3 Million
24/07/2025 02:37
July 24 (Reuters) - Bioxyne Ltd BXN.AX: FY25 UNAUDITED REVENUE OF A$29.3 MILLION Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: Bioxyne Secures A$50M Exclusive German Supply Agreement With Adrex
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal